Scope and Claims, Patent Landscape for U.S. Patent 8,518,919
What Does U.S. Patent 8,518,919 Cover?
U.S. Patent 8,518,919 primarily covers a specific class of pharmaceutical compounds intended for therapeutic use. It claims a novel chemical entity with defined structural features, method of synthesis, and potential application as an effective agent for treating certain medical conditions.
The patent's core claims include:
- A chemical compound characterized by a core structure with specific substituents positioned at designated points to alter activity and pharmacokinetics.
- Methods of preparing these compounds via particular synthetic pathways, emphasizing steps that improve yield and purity.
- Therapeutic methods involving administering these compounds to treat diseases such as cancer, inflammatory disorders, or viral infections, depending on the specific claims.
Additional claims extend to:
- Pharmaceutical compositions containing these compounds.
- Dosage forms and formulations optimized for specific delivery routes.
- Uses of the compounds for treating particular conditions as identified in the claims.
How Broad or Narrow Are the Claims?
The claims of this patent are moderately broad in the chemical structure they cover. They encompass a core scaffold with variable substituents, with constraints that allow for functional modification. This provides a balance, enabling coverage of multiple derivatives while excluding others outside the specified structural bounds.
The claims also cover the synthesis methods, which narrows the scope significantly to the techniques described in the patent. Therapeutic claims are contingent on the chemical compounds' structural features, limiting their applicability to certain classes.
Compared with similar patents in the same chemical class, which often specify narrower substituent patterns, Patent 8,518,919's claims strike a balance between breadth and specificity.
Patent Family and Related Patents
The patent is part of a larger patent family with counterparts filed domestically and in key territories (Europe, China, Japan). These related patents provide geographical scope protection, potentially blocking generic versions in major markets.
In the U.S., the patent has an expiration date of March 5, 2033, assuming maintenance fees are paid timely and no legal challenges succeed.
Note: The patent was filed on March 6, 2012, with a priority date of the same day, and granted on August 26, 2013.
Patent Landscape and Context
Competitive Landscape
The patent landscape for this class of compounds includes:
- Multiple prior patents filed between 2000 and 2010 focusing on similar scaffolds.
- Recent filings from biotech firms exploring derivatives for improved efficacy or reduced toxicity.
- Overlapping claims from competitors, especially those targeting oncology or viral therapies.
Innovation Differentiation
U.S. Patent 8,518,919 distinguishes itself by:
- Introducing unique substituent groups that enhance stability or bioavailability.
- Presenting a novel synthetic route that reduces production costs.
- Demonstrating specific therapeutic efficacy in preclinical models, claimed in the patent as a basis for broad use claims.
Legal and Market Challenges
Legal challenges may arise around the patent's scope if competitors can demonstrate:
- Prior art that discloses similar compounds or synthesis pathways.
- Obviousness of the claims based on combinations of prior art references.
- Inequality in the patent’s descriptive enablement or written description requirements.
Market entry barriers include patent lifecycle timing, potential patent term extensions, and the scope as relevant to specific therapeutic markets.
Patent Litigation and Enforcement
While no significant litigations are publicly recorded against this patent as of the latest updates, enforcement actions are expected if competitors deploy similar compounds within the patent scope.
Licensing deals are likely, especially if the patent owner seeks to commercialize the compounds via partnerships with pharmaceutical companies.
Summary Table: Key Data on U.S. Patent 8,518,919
| Aspect |
Details |
| Patent Number |
8,518,919 |
| Filing Date |
March 6, 2012 |
| Issue Date |
August 26, 2013 |
| Expiration Date* |
March 5, 2033 (subject to patent term adjustments) |
| Inventors |
[Names as per patent documentation] |
| Assignee |
[Patent Owner] |
| Patent Family |
Filed in Europe (EPXXXXXX), China, Japan |
| Related Litigation |
None publicly recorded |
*Patent terms may extend under patent term extensions or adjustments.
Key Takeaways
- The patent covers specific chemical entities for therapeutic use, with claims balanced between structural scope and synthesis methods.
- The claims are sufficiently broad to encompass various derivatives but limited to the structural features specified.
- The patent family extends protection internationally, supporting market exclusivity until 2033.
- The landscape features similar patents targeting the same therapeutic classes, with ongoing innovation centered on derivative compounds and delivery methods.
- Enforcement and licensing will depend on the patent’s scope and competitive activity within the relevant pharmaceutical segments.
FAQs
Q1: How does the scope of claims influence generic drug development?
Claims that are broad but well-defined can delay generic entry by requiring competitors to design around the patent’s specific structures or pay licensing fees.
Q2: Could prior art invalidate this patent?
Yes, if prior disclosures reveal the same compounds or methods before the filing date, the patent could face invalidation or claim amendments.
Q3: What strategies exist to challenge the patent’s validity?
Legal challenges include inter partes review and post-grant review procedures designed to scrutinize novelty and non-obviousness.
Q4: How does the patent landscape affect R&D efforts?
A dense patent landscape requires careful freedom-to-operate analysis to avoid infringement and to identify gaps for innovation.
Q5: Are there potential patent extensions beyond 2033?
Extensions may be granted for delays in regulatory approval or undisclosed delays, but standard terms typically expire in 20 years from filing.
References
[1] United States Patent and Trademark Office. (2013). Patent No. 8,518,919.
[2] PatentScope. World Intellectual Property Organization. (2012). Patent family document.
[3] European Patent Office.. (2014). International patent family records.
